Showing results (371-380 of 603) with videos related to

Sort By:
Pageof 61
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 6, 2019
Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs InvolvedAbdullah S Al Saleh, M Hasib Sidiqi, Eli Muchtar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 13, 2025
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survivalMatthew J Rees, Nadia Toumeh, Angela Dispenzieri, et al.
Transplantation and Cellular Therapy|May 18, 2025
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell TransplantAnmol Baranwal, Christopher Graham, Khalil Hassan, et al.
American Journal of Hematology|August 12, 2014
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasiasTaxiarchis V Kourelis, Shaji K Kumar, Ronald S Go, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2016
Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal GammopathiesLarissa S Higgins, Ronald S Go, David Dingli, et al.
Bone Marrow Transplantation|November 4, 2018
Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantationM Hasib Sidiqi, Mohammed A Aljama, Eli Muchtar, et al.
American Journal of Hematology|November 13, 2014
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosisGregory P Kaufman, Angela Dispenzieri, Morie A Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple MyelomaSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Blood Cancer Journal|April 12, 2022
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantationAbdullah S Al Saleh, Mohammad S Ebraheem, M Hasib Sidiqi, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Pageof 61